Tech Company Financing Transactions
Sedivention Funding Round
Sedivention, based in Strasslach, received $3.4 million from Cambridge Capital, High-Tech Gründerfonds and SuperAngel.vc.
Transaction Overview
Company Name
Announced On
5/11/2026
Transaction Type
Venture Equity
Amount
$3,400,000
Round
Seed
Investors
Cambridge Capital (Lead Investor)
High-Tech Gründerfonds (Lead Investor)
SuperAngel.vc (Lead Investor)
Proceeds Purpose
The company intends to use the funds to further develop its novel outpatient therapy for treating obesity and generate initial clinical data to prepare for market entry.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
Hugo-Hofmann-Str. 56
Strasslach, D-82064
Germany
Strasslach, D-82064
Germany
Phone
Undisclosed
Website
Email Address
Overview
Our business: a new innovative therapy for losing weight. A team of experienced engineers and physicians is developing a medical device for a minimally invasive, outpatient interventional treatment of obesity. Simple and without major risks and side effects. A protype has already been developed and successfully tested for safety and efficacy. Several awards reflect our innovative approach.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andreas Bröcker
Chief Marketing Officer
Ute Nollert
Co-Founder
André Burch
Browse more venture capital transactions:
Prev: 5/11/2026: Enter venture capital transaction
Next: 5/11/2026: PIASPACE venture capital transaction
Share this article
About Our VC Transactions Data
We report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs